NATALIYA OSORIO: Open Payments
NPI 1861009797 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,804 in 142 payments from 20 companies in 2025. Trend: 2023 $3,863 · 2024 $1,115 · 2025 $3,804
Food & beverage: $2,927Travel & lodging: $877
| Company | Payments | Amount |
|---|---|---|
| LivaNova USA, Inc. | 3 | $1,138 |
| ABBVIE INC. | 45 | $689 |
| ACADIA Pharmaceuticals Inc | 25 | $357 |
| Amneal Pharmaceuticals LLC | 10 | $344 |
| MDD US Operations, LLC | 9 | $206 |
| Novartis Pharmaceuticals Corporation | 14 | $188 |
| SK Life Science, Inc. | 4 | $160 |
| ARGENX US, INC. | 7 | $155 |
| Lundbeck LLC | 3 | $83 |
| UCB, Inc. | 2 | $70 |
Products named: VNS Therapy, QULIPTA, NUPLAZID, CREXONT, KESIMPTA, VYVGART HYTRULO, XCOPRI, VYEPTI.
Industry payments across CA — which companies pay providers there.
